Pharmicell Co., Ltd.
005690
Rank in Stocks
#13659
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a... Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.
Share Price
$6.22
Last synced: 2026-11-10
Market Cap
$373.14M
Change (1 day)
4.11%
Change (1 year)
-48.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharmicell Co., Ltd. (005690)
Category
Healthcare
Operating Margin for Pharmicell Co., Ltd. (005690)
Operating Margin as of November 2026 TTM: 32.38%
According to Pharmicell Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 32.38%. At the end of 2025 the company had an operating margin of 29.61%.
Operating Margin history for Pharmicell Co., Ltd. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 32.38% | 9.35% |
| 2025 | 29.61% | 312.40% |
| 2024 | 7.18% | 324.85% |
| 2023 | 1.69% | -88.53% |
| 2022 | 14.74% | -2.90% |
| 2021 | 15.18% | -20.77% |
| 2020 | 19.16% | 216.69% |
| 2019 | 6.05% | 557.61% |
| 2018 | 0.92% | -105.20% |
| 2017 | -17.70% | 164.18% |
| 2016 | -6.70% | -69.50% |
| 2015 | -21.97% | -47.39% |
| 2014 | -41.76% | 82.68% |
| 2013 | -22.86% | -81.90% |
| 2012 | -126.28% | -20.39% |
| 2011 | -158.62% | 9.92% |
| 2010 | -144.31% | 317.20% |
| 2009 | -34.59% | -13.76% |
| 2008 | -40.11% | 138.32% |
| 2007 | -16.83% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -105.60% |
US
|
|
| 38.59% | -98.81% |
US
|
|
| -149.01% | -104.60% |
US
|
|
| 25.57% | -99.21% |
AU
|
|
| 31.23% | -99.04% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pharmicell Co., Ltd.'s operating margin
What is Pharmicell Co., Ltd.'s operating margin?
Pharmicell Co., Ltd.'s operating margin is 32.38%, as of Nov 2026.
What was Pharmicell Co., Ltd.'s operating margin in 2025?
In 2025, Pharmicell Co., Ltd.'s operating margin was 29.61%, compared with 7.18% in 2024.
How has Pharmicell Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Pharmicell Co., Ltd.'s operating margin was highest in 2025 (29.61%) and lowest in 2023 (1.69%).
How does Pharmicell Co., Ltd.'s operating margin compare with similar companies?
Pharmicell Co., Ltd.'s operating margin (32.38%) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.